Cystic Fibrosis foundation lays out new treatment ...( New clinical standards on the treatm...),Health
New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.
The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the second issue for November of the American Thoracic Societys American Journal of Respiratory and Critical Care Medicine.
CF is a complex genetic disease affecting the lungs and other organs, and is characterized by an unusually thick, sticky mucus that renders CF victims virtually incapable of fending off infections and pathogens. CF is always fatal, but thanks to advances in treatment in the last 60 years, life expectancy has increased from just a few years to 36 years. Lung disease accounts for 85 percent of the mortality among CF patients.
"Physicians treating patients with CF are faced with a growing number of treatment options" wrote lead author of the guidelines, Patrick A. Flume, M.D. "We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF."
The pulmonary guidelines committee assessed the clinical efficacy and safety of the use of aerosolized antibiotics, recombinant human DNase (dornase alfa), hypertonic saline inhalation, anti-inflammatory agents, macrolide antibiotics, the use of bronchodilators and N-acetylcysteine. They analyzed the clinical results with regard to the number of studies, strength of the study designs and the quality and consistency of results to make their final recommendations. Because of the general dearth of studies on treatments in children under the age of six, the committee restricted their recommendations to CF patients six years of age and older.
The treatments with the strongest, most consistent results yielding an "A"-grade positive recommendation were:
- Inhaled tobramycin, an antibiotic, to suppress chron
'/>"/>
| Contact: Suzy Martin smartin@thoracic.org 212-315-8631 American Thoracic Society Source:Eurekalert |
Related medicine news :
1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
6. Liver fibrosis will be treated by a potential target
7. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
8. MRI predicts liver fibrosis, study says
9. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
10. National Patient Safety Foundation Partners with Vocera Communications
11. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |